Banisteriopsis caapi
Viewing r2 — May 14, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Ayahuasca vine (Banisteriopsis caapi, Malpighiaceae) — caapi, yagé — is a woody liana native to Amazonian rainforest whose stems and bark are prepared as psychoactive decoctions. Its primary active constituents are β-carboline alkaloids, principally harmine, which act as potent reversible MAO-A inhibitors. Harmine produces its principal effects by blocking monoamine oxidase A, preventing serotonin breakdown and — in combination preparations — enabling oral bioavailability of co-administered DMT.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
B. caapi has been used for ceremonial and healing purposes by Amazonian indigenous peoples for millennia.[1] The 1996 Hoasca Project provided the first human pharmacokinetic data for ritual ayahuasca,[2] and a 2018 trial demonstrated significant antidepressant effects in treatment-resistant depression.[3] Religious use is legally protected in Brazil since 1987 and in the United States under a 2006 Supreme Court ruling.[4]
When combined with a DMT-containing admixture plant, B. caapi produces intense visual and auditory perceptual modification, cognitive amplification, emotional intensification, and deep introspection. The experience is distinctly multi-layered — a convergence of somatic, perceptual, and psychological effects shaped by set, setting, and ceremonial context. Pronounced nausea and vomiting are characteristic unsought effects, occurring in a majority of users.[5]
No physical dependence or withdrawal has been documented; long-term ritual users show no cognitive impairment or addiction-related problems.[6] The principal safety concern is MAO-A inhibition creating mechanistic risk for serotonin syndrome with concurrent serotonergic medications.[7] Clinical evidence derives almost entirely from ayahuasca preparations containing DMT admixture; no published pharmacokinetic data exist for B. caapi-only preparations.
History[edit]
Traditional and historical use
Banisteriopsis caapi has been used for ceremonial, healing, and divinatory purposes by numerous Amazonian indigenous peoples. Phylogenetic evidence supports millennia-old exchange of use among Amazonian populations, with no indication of human manipulation in the species' diversification — suggesting management of a naturally occurring plant rather than deliberate domestication.[1] Traditional names reflect broad geographic distribution: ayahuasca (Quechua: "vine of the soul"), caapi (Tupí), yajé or yagé (Colombian indigenous groups), and natema (Shuar). Documented user populations include the Shipibo-Conibo, Shuar, Siona-Secoya, Cofán, and many other Amazonian nations.[8]
The traditional preparation involves extended boiling of pounded B. caapi vine stalks and bark, usually combined with leaves of Psychotria viridis or other DMT-containing plants to produce the classic ayahuasca decoction. Curanderos and vegetalistas (Mestizo-tradition healers) integrate B. caapi into healing practices alongside prescribed dietary regimens known as dietas.[8][9]
Western discovery and research
The British botanist Richard Spruce first collected B. caapi during Amazonian expeditions in the early 1850s.citation needed August Grisebach formally described the specimen as Banisteria caapi, and Conrad Vernon Morton reclassified it to Banisteriopsis in 1931.[10] Schultes consolidated the ethnobotanical record in 1957, establishing B. caapi's central role in Amazonian psychoactive plant use.[11]
The Hoasca Project (1996) — a collaboration between McKenna, Callaway, Grob, and colleagues — measured harmala alkaloid and DMT plasma levels in 15 members of the Brazilian União do Vegetal church, producing the first human pharmacokinetic data for ritual ayahuasca.[2] Riba and colleagues in Barcelona subsequently conducted the first double-blind placebo-controlled studies of ayahuasca in healthy volunteers.[12][13]
Modern era
The 20th century saw the emergence of Brazilian syncretic religions centred on ayahuasca as a sacrament. Santo Daime, founded by Raimundo Irineu Serra in the 1930s, and União do Vegetal (UDV), founded by José Gabriel da Costa in 1961, have exported ayahuasca ceremony to North America, Europe, and beyond.[4]
- 1987 — Brazil's CONAD formally recognized ayahuasca for religious use[4]
- 2006 — US Supreme Court upheld RFRA exemption for UDV in Gonzales v. O Centro Espírita Beneficente União do Vegetal[4]
- 2008 — Peru declared ayahuasca part of national cultural heritage[4]
- 2018 — First placebo-controlled randomized trial demonstrated significant antidepressant effects in treatment-resistant depression[3]
- 2023 — Church of Gaia received DEA religious exemption for sacramental ayahuasca use in the United States[4]
Botanical Overview[edit]
Banisteriopsis caapi (Spruce ex Griseb.) C.V.Morton is a large woody liana (climbing vine) of the family Malpighiaceae. Originally described as Banisteria caapi by Grisebach, it was reclassified into the genus Banisteriopsis by Morton in 1931.[10] Multiple cultivar varieties are recognized by indigenous growers — distinguished primarily by bark colour, stem diameter, and growth habit — though formal taxonomic subdivision below the species level is not well established.
The vine is native to lowland tropical rainforest across Bolivia, Brazil, Colombia, Ecuador, Peru, and Venezuela. It thrives in moist, shaded conditions, climbing canopy trees as a large woody stem that can reach several centimetres in diameter and extend high into the forest canopy. B. caapi is actively cultivated throughout its native range by indigenous communities and at ayahuasca-retreat sites; wild populations are affected by broader Amazonian habitat loss but the species is not considered endangered.
B. caapi is identified by smooth to lightly fissured bark, opposite ovate leaves, and clusters of small pink to pale flowers. A distinctive cross-section pattern — sometimes described as a "ladder" or "staircase" motif in the woody interior — is used by indigenous harvesters to distinguish B. caapi from superficially similar Malpighiaceae lianas in the same habitat.
For psychoactive preparation, sections of mature stem and bark are harvested and typically pounded or shredded to expose inner tissue before boiling. Stem age and harvest timing influence alkaloid content; further preparation details are covered in the Preparations section.
Alkaloid Profile[edit]
Harmine is the dominant alkaloid in B. caapi, present at a mean concentration of 4.79 mg/g dried liana.[14] It functions as a potent reversible MAO-A inhibitor at low nanomolar concentrations.[15] In ayahuasca preparations, this MAO-A inhibition prevents gastrointestinal and hepatic deamination of DMT contributed by the admixture plant, enabling oral bioavailability of an otherwise orally inactive tryptamine.[12]
The B. caapi alkaloid profile operates as a functional system rather than a single-compound action. Harmine provides the primary MAO-A blockade; tetrahydroharmine (THH) contributes secondary serotonin reuptake inhibitor with an SSRI-like mechanism; and harmaline adds weaker MAO-A inhibition.[7] This three-alkaloid combination produces a layered pharmacological effect — harmine and harmaline block the enzyme that would destroy orally ingested DMT, while THH modulates mood through an independent serotonergic pathway.
Beyond the MAO-A axis, harmine acts as a 5-HT₂A receptor agonist at higher concentrations and augments dopamine efflux in the nucleus accumbens via a presynaptic 5-HT₂A-dependent mechanism that is independent of its MAOI activity.[16] Harmaline exhibits anti-inflammatory activity through COX inhibition, nitric oxide pathway suppression, and Nrf-2/antioxidant signalling activation.[17] Harmine is also a potent inhibitor of DYRK1A, a kinase of potential relevance to neurodevelopmental and neurodegenerative disease research.citation needed
Alkaloid concentrations in B. caapi are extremely variable. Relative standard deviations of 78.9–170% across batches have been documented,[14] meaning a dose calibrated from one batch may deliver substantially different alkaloid quantities from another. Cultivar, growing conditions, harvest timing, and stem age all influence concentration. This variability is the primary practical challenge for dosing accuracy with any B. caapi preparation.
Neuroscience[edit]
Where it acts
B. caapi's β-carbolines target the monoamine oxidase system. Harmine's reversible MAO-A inhibition raises synaptic serotonin, norepinephrine, and dopamine by preventing their enzymatic breakdown.[15][7] In full ayahuasca, this peripheral MAO-A blockade enables DMT to survive first-pass metabolism and reach the brain, where it activates 5-HT₂A receptors across the cortex.[12] THH adds a second serotonergic layer through SSRI-like reuptake inhibitor.[7]
What it changes
Functional MRI studies show that ayahuasca decreases default mode network (DMN) activity — including the posterior cingulate cortex and medial prefrontal cortex — with reduced connectivity within the precuneus.[18] Broader neuroimaging review confirms acute excitation of frontolateral cortex, medial temporal lobe, and occipital cortex alongside this DMN suppression,[19] a pattern that may underlie the dissolution of habitual self-referential thought and vivid internal imagery.
B. caapi alkaloids (harmine, THH, harmaline, and the harmine metabolite harmol) stimulate adult neurogenesis in vitro — promoting neural stem cell proliferation, migration, and differentiation.[20] Post-acute enhancements in mindfulness capacity and persistent DMN modifications have been documented at 24 hours after administration.[21]
- No pharmacokinetic data exist for B. caapi-only preparations — all published human data derive from ayahuasca or standardized DMT+harmine formulations.
- The clinical significance of harmine's CYP2D6 and CYP3A4 inhibition relative to its MAO-A inhibition remains uncharacterized.
- Whether the neurogenesis observed in vitro translates to clinically relevant structural neuroplasticity in humans has not been established.
Subjective Effects[edit]
The experiential character of B. caapi preparations depends fundamentally on whether DMT-containing admixture plants are present. Classic ayahuasca — B. caapi combined with Psychotria viridis — produces a dense, multi-layered state integrating intense visual and auditory perceptual shifts, emotional enhancement, introspective depth, and prominent gastrointestinal activation. B. caapi alone reportedly produces primarily somatic and introspective effects without intense visual hallucination, though no controlled clinical data exist for this preparation. Set, setting, and ceremonial container exert unusually strong influence on experience quality; batch-to-batch alkaloid variability (RSD 78.9–170%) further ensures that no two sessions are pharmacologically identical.[14]
Ayahuasca occupies a distinct position among serotonergic psychedelics. Where psilocybin or LSD acts primarily through direct 5-HT₂A agonism, ayahuasca's pharmacology is a multi-compound interaction — reversible MAO-A inhibition enabling oral DMT activity, layered with THH's serotonin reuptake inhibitor. This mechanistic complexity, combined with the pronounced nausea and purging, distinguishes it from all synthetic tryptamine and lysergamide experiences.
Effect Grid
At common doses — the 0.6–0.85 mg DMT/kg range in controlled research, or a standard ceremonial serving of 50–100 mL — pronounced perceptual modification emerges. Geometry, internal hallucinations, color enhancement, and visual drifting become apparent. Auditory distortion and auditory enhancement develop. Cognitive effects include marked introspection enhancement, conceptual thinking, thought connectivity, and creativity enhancement. Emotional enhancement intensifies significantly, with catharsis commonly reported.
Nausea is likely at this level, with vomiting occurring in a majority of users in some surveys. Bodily heaviness, spontaneous body sensations, and motor control impairment are common. Diastolic blood pressure increases approximately 9 mmHg. Trembling and excessive sweating may occur. Physical fatigue develops during offset.
Total duration is 4–6 hours. Set and setting strongly influence experience quality. Batch variability (RSD 78.9–170%) means identical volumes from different preparations may produce substantially different intensity levels.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Internal hallucinations · External hallucinations
Dizziness · Involuntary body movements · Physical fatigue · Trembling · Body high · Nystagmus (eye wobbles) · Sedation · Spontaneous body sensations · Excessive sweating · Salivation · Stimulation · Tingling / electric sensations · Vibrations / buzzing · Heart rate perception changes · Restlessness · Headache · Pain suppression
Body high · Nystagmus (eye wobbles) · Sedation · Spontaneous body sensations · Excessive sweating · Salivation · Stimulation · Tingling / electric sensations · Vibrations / buzzing · Heart rate perception changes · Restlessness · Headache · Pain suppression
Increased nature relatedness · Openness enhancement · Aesthetic enhancement · Confusion · Creativity enhancement
Creativity enhancement
Anxiety · Dysphoria
Timeline · by preparation
Preparations[edit]
Traditional ayahuasca decoction
Traditional ayahuasca is prepared by extended boiling (typically 8–12+ hours) of pounded or shredded B. caapi stems and bark, combined with leaves of Psychotria viridis or other DMT-containing admixture plants.[8][9] The resulting brew varies widely in alkaloid concentration depending on plant material quantity, boiling duration, and water volume. Onset occurs within 30–60 minutes; effects peak at approximately 1.5–2 hours and resolve within 4–6 hours.[12] Nausea and vomiting are expected and occur in a majority of users. Traditional preparations are dose-calibrated by experienced practitioners (curanderos or vegetalistas), not by standardized measurement.
B. caapi-only decoction
B. caapi-only decoctions, prepared without DMT-containing admixture, are documented among some indigenous groups. These preparations produce primarily somatic and mild introspective effects without the intense visual hallucinations characteristic of full ayahuasca. No published pharmacokinetic data or controlled dose-ranging studies exist for this preparation form; dosing relies entirely on traditional practitioner judgment.
Standardized research formulations
Encapsulated ayahuasca at standardized doses (0.6–0.85 mg DMT/kg body weight) has been used in controlled clinical trials.[12] Buccal DMT+harmine formulations (DMT 0–120 mg, harmine 0–180 mg) have also been studied, producing comparable effect timelines of 4–5 hours with more consistent alkaloid delivery than traditional decoctions.[22] Buccal administration produced peak DMT cmax of 33 ng/mL and harmine cmax of 49 ng/mL.[22]
Commercial vine products
Commercial B. caapi products — dried shredded vine, vine extract, and pre-prepared brew concentrates — are sold through online botanical retailers. No standardization framework, Certificate of Analysis requirement, or accredited testing program exists for these products.[23][24] Alkaloid content is variable and typically unlabelled. Batch-to-batch variability (RSD 78.9–170%) means a dose calibrated on one product may deliver substantially different alkaloid quantities from another.[14]
Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- slow
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- DMT · psilo · LSD
Toxicity
No published human LD50 data exist for B. caapi or ayahuasca. A systematic review found no case in which autopsy and toxicological examination together attributed death to ayahuasca alone.[23] In vitro cytotoxicity appeared only at harmine concentrations far exceeding therapeutic plasma levels.[25][2]
The most frequently reported acute physiological effect is nausea and vomiting, occurring in a majority of users.[5] At higher doses, a diastolic blood pressure increase of approximately 9 mmHg has been observed, along with mild sympathomimetic effects including pupil dilation, prolactin elevation, and cortisol elevation.[12][26] Transient lymphocyte modulation (NK cell increase, CD4 and CD3 decrease) has been documented, returning to baseline within 24 hours.[26]
No significant alteration in liver function tests was found in chronic users consuming ayahuasca twice monthly for at least one year.[27]
No systematic studies on pesticide contamination, heavy metal content (lead, cadmium, arsenic, mercury), or mycotoxin contamination in commercial B. caapi preparations have been published.safety citation needed No standardization framework, Certificate of Analysis requirement, or ISO/IEC-accredited testing program exists for commercial products.[23][24] Commercially sold preparations may contain variable and unlabelled amounts of active alkaloids. This constitutes a practical safety gap, particularly for non-ceremonial use where experienced dose calibration by a traditional practitioner is absent.
Psychological Risks
Acute anxiety, transient confusion, and panic reactions are commonly reported even at standard ayahuasca doses.[13] In a cross-sectional study of 614 religious users, the most frequent adverse effects were transient gastrointestinal symptoms; a minority reported being "very negatively affected" by persistent adverse effects.[5] Adverse effects were more frequent in participants with pre-existing psychiatric diagnoses, although psychiatric medication use was not statistically associated with increased adverse effect frequency in this sample.[5]
Risk of acute psychological crisis is elevated in individuals with personal or family history of psychotic disorders, bipolar disorder type I, or severe psychiatric illness.[28][8] A scoping review identified psychological adverse reactions as the primary documented concern for travellers using ayahuasca in non-ceremonial settings.[28]
Tolerance & Dependence
No physical dependence or withdrawal has been documented for B. caapi or ayahuasca.[8][6] Long-term ritual users consuming ayahuasca at least twice monthly show no cognitive impairment and no addiction-related problems.[6] Preserved or improved cognitive function — including enhanced working memory — has been confirmed in long-term users compared with beginners.[29]
Naive users assessed at 1 and 6 months after first use showed improvements in mental health measures.[30] Tolerance to DMT's psychedelic effects develops with repeated acute dosing; tolerance to MAO-A inhibition by harmine has not been systematically studied.
Drug Interactions
B. caapi's harmine and harmaline are reversible MAO-A inhibitors. This mechanism creates the primary herb-drug interaction risk.
Serotonergic agents: MAO-A inhibition combined with serotonin reuptake inhibitor or serotonin release increases synaptic serotonin, creating mechanistic risk for serotonin syndrome — a potentially life-threatening condition characterised by hyperthermia, agitation, clonus, and hyperreflexia. Affected drug classes include SSRIs, SNRIs, triptans, tramadol, meperidine, and dextromethorphan.[7][15] The interaction severity is based on mechanistic inference from the MAOI pharmacology class.safety citation needed
Tyramine-containing foods: MAO-A normally catabolises dietary tyramine; inhibition may produce hypertensive crisis. B. caapi produces reversible (not irreversible) MAO-A inhibition, and no hypertensive crises were documented among 614 religious users.[5] The magnitude of tyramine interaction from reversible MAO-A inhibition versus irreversible pharmaceutical MAOIs remains uncharacterised.safety citation needed
Sympathomimetics: Amphetamines, cocaine, and other sympathomimetic agents may produce augmented dopaminergic and noradrenergic effects via reduced MAO-A catabolism.safety citation needed
CYP2D6 and CYP3A4 substrates: Harmine inhibits CYP2D6 and CYP3A4 in vitro, potentially elevating plasma levels of co-administered medications including certain antipsychotics, antidepressants, and opioids.safety citation needed
Lithium: Anecdotal reports in the broader psychedelic literature suggest seizure and cardiac risk with lithium combined with psychedelics.safety citation needed
Contraindications
''Absolute:''
- Personal history of psychotic disorders or bipolar disorder type I: Elevated risk of psychosis precipitation and acute adverse psychological reactions[28][8]
- Concurrent serotonergic medication (SSRIs, SNRIs, triptans, tramadol, dextromethorphan): Mechanistic risk of serotonin syndrome via MAO-A inhibition combined with serotonin reuptake blockade or release[7]
''Relative:''
- Severe cardiovascular disease: Diastolic blood pressure increase (~9 mmHg) and sympathomimetic activation documented at standard doses[12]
- Family history of psychotic disorders: Elevated psychological risk based on clinical risk assessment literature[8]
- Concurrent lithium use: Uncharacterised seizure and cardiac risk reported anecdotally in the broader psychedelic literaturesafety citation needed
- Pregnancy: No reproductive safety data exist for B. caapi or ayahuasca; MAO-A inhibition and serotonergic modulation present theoretical fetal risksafety citation needed
- Hepatic impairment: Potential for altered harmine metabolism and prolonged MAO-A inhibitory effectsafety citation needed
''Detection:''
Harmala alkaloids (harmine, harmaline, THH) serve as more reliable biomarkers than DMT for identifying ayahuasca exposure in forensic urine screens, due to DMT's short plasma half-life.[31] Hair analysis via dispersive liquid-liquid microextraction can detect DMT, harmine, harmaline, and THH at pg/mg concentrations, with β-carbolines detected at higher concentrations than DMT.[32]
Harm Reduction[edit]
Forms & Identification
B. caapi is sold as dried shredded vine, whole vine sections, powdered bark, and pre-prepared liquid concentrates. No ISO/IEC-accredited testing program or Certificate of Analysis standard exists for any commercial B. caapi product. Because alkaloid concentrations vary by 78.9–170% RSD across batches,[14] a product that appeared mild in one batch may be significantly stronger in the next. When purchasing commercial products, request lab-tested preparations with specified harmine, harmaline, and THH concentrations where available. For traditional ceremonial preparations, alkaloid consistency depends entirely on the preparer's experience and the sourcing of vine material.
Guidelines
- Start with a small portion of any new preparation source before committing to a full dose — alkaloid content is unpredictable across batches[14]
- Observe a washout period of at least 2 weeks from any serotonergic medication (5 weeks for fluoxetine) before using any B. caapi preparation
- Follow traditional dietary precautions (dieta): avoid tyramine-rich foods (aged cheese, cured meats, fermented products) for at least 24 hours before and after use
- Do not combine with alcohol, stimulants, or other psychoactive substances
- Ensure access to water and a comfortable space where nausea and vomiting can be managed safely
- Have a sober, trusted companion present for the full duration of effects
- Allow 4–6 hours for the experience; do not drive or operate machinery until effects have fully resolved
Set & Setting
Ayahuasca ceremonies are traditionally conducted in controlled environments with experienced facilitators who manage both the physical and psychological dimensions of the experience. The intense effects — prolonged nausea, vivid perceptual shifts, and emotional enhancement — are strongly modulated by environment and mental state. First-time users should ensure a trusted, sober companion is present throughout. Avoid use during periods of acute psychological distress, bereavement, or mental health instability. Non-ceremonial settings without experienced facilitation carry elevated risk of psychological adverse reactions.[28]
Aftercare & integration. Ayahuasca experiences can be psychologically intense, and residual emotional processing commonly continues for days afterward. Maintain adequate hydration and eat bland, easily digestible food following the session. Expect fatigue and emotional sensitivity for 24–48 hours.
Integration — processing insights and emotional material that arose during the experience — benefits from journaling, conversation with a trusted person, or work with a therapist familiar with psychedelic experiences. Avoid major decisions or high-stress situations in the days following use. Post-acute enhancements in mindfulness capacity have been documented,[21] but challenging emotional content may also resurface and warrant professional support.
Recovery & Support
B. caapi and ayahuasca do not produce physical dependence or a characterised withdrawal.[8] However, if use has become compulsive or is interfering with daily functioning, reduce frequency gradually and seek professional support.
- SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7)
- Fireside Project: 62-FIRESIDE (psychedelic peer support line)
- ICEERS: International Center for Ethnobotanical Education, Research and Security — legal and safety resources for ayahuasca users
If persistent psychological disturbance follows use — including anxiety, depersonalisation, or mood instability lasting more than two weeks — consult a mental health professional with experience in psychedelic-related concerns.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency
Red flags requiring immediate medical attention:
- Sustained rigid muscle contractions or tremor with high fever (signs of serotonin syndrome)
- Unresponsiveness, seizure, or loss of consciousness
- Severe chest pain, rapid irregular heartbeat, or difficulty breathing
- Prolonged psychotic episode — the person cannot recognise surroundings, is a danger to themselves or others, or is in severe uncontrollable panic
Immediate steps
- 1. Move the person to a calm, safe environment
- 2. If serotonin syndrome is suspected (muscle rigidity, hyperthermia, agitation), call emergency services immediately — this is a medical emergency
- 3. Do not physically restrain the person unless they are at immediate risk of self-harm
- 4. Keep the person cool if body temperature is elevated; remove excess clothing
- 5. If conscious and oriented, reassure them calmly that the effects are temporary and time-limited
What to tell the dispatcher
State that the person consumed ayahuasca (a brew containing monoamine oxidase inhibitors and possibly DMT), the approximate time of ingestion, any medications taken in the preceding weeks, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who report drug-related emergencies.
No reversal agent exists for B. caapi alkaloids or DMT. Treatment is supportive.
Legal Status[edit]
DMT — the primary psychoactive compound in full ayahuasca preparations, contributed by admixture plants — is a Schedule I substance under the 1971 United Nations Convention on Psychotropic Substances.[4] The β-carboline alkaloids in B. caapi (harmine, harmaline, tetrahydroharmine) are not scheduled under any international treaty. The ayahuasca brew itself is not explicitly named in international drug control conventions. This creates complex jurisdictional variation: the vine is uncontrolled, but preparations containing DMT from admixture plants fall under national drug laws in most countries. Religious exemption jurisprudence provides the primary legal pathway for authorised use.
| Jurisdiction | Status | Notes |
|---|---|---|
| United States (federal) | DMT: Schedule I | Ayahuasca illegal via DMT content. B. caapi vine not federally scheduled. RFRA upheld for UDV in Gonzales v. O Centro (2006). Church of Gaia received DEA religious exemption (2023).[4] |
| United States (state) | Variable | No state has independently scheduled B. caapi vine. Federal DMT scheduling supersedes state-level permissiveness.citation needed |
| Brazil | Legal for religious use | CONAD recognised ayahuasca for religious use (1987); 2010 resolution clarified rules. Commercial and non-religious use remain prohibited.[4] |
| Peru | National cultural heritage | Declared cultural heritage in 2008. Significant legal protection for traditional use; ayahuasca tourism operates commercially.[4] |
| Colombia | No specific legislation | No specific legislation regulating ayahuasca. Retreats operate without legal interference in practice.[4] |
| Canada | DMT: Schedule III (CDSA) | Ayahuasca illegal by default. Religious exemption possible via Section 56 of CDSA.[4] |
| United Kingdom | DMT: Class A | All DMT-containing preparations strictly prohibited. No religious exemption established.[4] |
| Spain | Personal possession decriminalised | Import, sale, and cultivation remain illegal. Highest number of ayahuasca-related legal incidents in Europe.[4] |
| Portugal | Possession decriminalised | All drug possession decriminalised (2001). Import, sale, and cultivation of ayahuasca remain illegal.[4] |
| France | Prohibited | Regulatory lists include ayahuasca preparation plants. Full prohibition in effect.[4] |
| Netherlands | DMT: List I (Opium Act) | B. caapi vine not scheduled. Legal status of ayahuasca brew ambiguous; court outcomes have varied.citation needed |
| Germany | DMT controlled (BtMG) | Ayahuasca illegal. No religious exemption established.citation needed |
| Australia | DMT: Schedule 9 | Ayahuasca illegal. State-level enforcement variation may exist.citation needed |
Treaty considerations
The disjunction between international scheduling of DMT and the unscheduled status of B. caapi and the ayahuasca brew creates the principal legal ambiguity. B. caapi vine contains no DMT — its β-carboline alkaloids are not controlled under any international treaty. However, traditional preparations combining B. caapi with DMT-containing plants yield a brew containing a Schedule I substance, placing it under national drug control frameworks in most jurisdictions. Religious exemption jurisprudence (US RFRA, Brazilian CONAD, Canadian Section 56) provides the primary legal pathway for authorised use.
references
- [1] ^abSantos TAC et al. (2025) Dated Phylogeny of Banisteriopsis (Malpighiaceae) Suggests an Ancient Colonization of the Cerrado and No Evidence of Human Manipulation in the Origin of B. caapi — Plants doi:10.3390/plants14071149
- [2] ^abcCallaway JC et al. (1996) Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca — Journal of Analytical Toxicology PMID:8889686
- [3] ^abPalhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, et al. (2018) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial — Psychological Medicine doi:10.1017/s0033291718001356
- [4]
- [5]
- [6] ^abcBouso JC, González D, Fondevila S, et al. (2012) Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study — PLoS ONE doi:10.1371/journal.pone.0042421